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Abstract
With increasing global obesity, there is a growing body of research looking at 
the impact of this on reproduction. Both male and female fertility are impacted on 
by being overweight or obese. Although the pathophysiology is not clear, it appears 
that obesity impacts endocrine function in men and women, oocyte and sperm 
quality, embryo quality, endocrine receptivity, and implantation. Miscarriage, 
pregnancy, and live birth rates and the risk of congenital malformations are all 
influenced by obesity. Transgenerational health is also affected, with metabolic, 
endocrine, and reproductive outcomes in the offspring being negatively affected by 
both paternal and maternal obesity. It appears that weight loss results in improve-
ments in these outcomes and various strategies have been employed including 
lifestyle and behavior modification, pharmacological agents, and also bariatric 
surgery. This chapter aims to explore the reproductive outcomes of obesity and how 
this can be best managed to improve outcomes.
Keywords: obesity, IVF, embryos, bariatric, fertility, offspring, reproduction, 
lifestyle, oocyte, sperm
1. Introduction
Overweight or obesity is defined as an accumulation of excess body fat that 
poses a risk for health [1]. A measure often used in assessment of this is the body 
mass index (BMI), which is a person’s weight in kilograms divided by height in 
meters squared (kg/m2). Obesity is a BMI greater than 30 and overweight is a BMI 
greater than 25, although in South East Asian populations, it is generally accepted 
that the upper limit of normal is a BMI of 23.
Globally, 39% of adults over 18 years are overweight and 13% are obese, 
and worldwide, obesity has tripled since the 1970s [2]. Being overweight or 
obese is directly linked to a greater risk of mortality and disease than being 
underweight.
Infertility is defined as failure to achieve a clinical pregnancy after 12 months 
or more of regular unprotected sexual intercourse [3]. Globally, at least 50 million 
couples worldwide experience infertility, with the burden affecting up to one in 
four couples in developing nations. The overall prevalence of infertility does not 
appear to have changed since the 1990s.
Overweight or obesity is understood to impact on both female and male repro-
ductive health, and mounting research demonstrates that this impact will extend to 
the health and reproductive outcomes of future generations.
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2. Effects of obesity on female reproduction
2.1 Hormonal effects of obesity
Menstrual irregularities occur more frequently in women who are overweight. 
This is due to a functional alteration to the hypothalamic-pituitary-ovarian (HPO) 
axis from various factors. Firstly, obesity induces a hyperinsulinemic state, separate 
to polycystic ovarian syndrome (PCOS). Hyperinsulinemia leads to a suppression 
in serum hormone binding globulin (SHBG), which results in an increase in bioac-
tive androgens. These androgens are subsequently aromatized within body fat to 
estrogen, which suppresses gonadotrophins produced by the pituitary [4].
Elevated androgens in PCOS also lead to an increased deposition of visceral fat, 
exacerbating insulin resistance and hyperinsulinemia, further stimulating androgen 
production and perpetuating the cycle of pituitary suppression [5].
Additionally, adipokines, cytokines produced from adipose tissue, are known 
to impact on ovulation. Obese women have higher levels of circulating leptin, a 
cell- signaling protein from adipose tissue, than normal weight women, and this can 
therefore mean a chronic downregulation of the receptor in the hypothalamus, [6] 
resulting in suppression of the HPO axis activity. A study of eumenorrheic obese 
women demonstrated that the amplitude of luteinizing hormone (LH) pulses was 
significantly reduced compared with normal weight women, again pointing to a 
central defect [7].
Obese women remain subfertile even if they are ovulatory. Two studies in large 
cohorts of Danish women showed a decline in fecundability ratios with increasing 
BMI [8, 9]. Another large American cohort [10] along with a Dutch cohort of over 
3000 women [11] also demonstrated a linear decline in spontaneous conception 
rates with rising BMI.
Consequently, there are other factors at play that affect fertility in overweight 
and obese women.
2.2 Effects of obesity on oocyte quality
Data show that being overweight or obese can have profound impact on oocyte 
quality. A study of over 45,000 assisted reproduction transfers demonstrated that a 
higher BMI resulted in a lower likelihood of successful pregnancy when autologous 
oocytes were used but not when oocytes from lean donors were used [12]. This has 
been demonstrated in other research as well [13].
Studies also suggest that obese women in in vitro fertilization (IVF) cycles require 
higher levels of gonadotrophin stimulation and longer treatment to achieve an oocyte 
retrieval [14]. This is also the case in superovulation for intrauterine insemination 
cycles [15]. Obese women also have a greater risk of cycle cancelation, lesser oocytes 
collected, and lesser oocyte maturity than normal weight women [16–18].
Several mechanisms are believed to impact on the oocyte quality in obese 
women.
Obesity is an inflammatory state where women have higher circulating levels of 
C-reactive protein (CRP), which is an inflammatory biomarker. Adipose tissue pro-
duces many proinflammatory adipokines including leptin, tumor necrosis factor alpha 
(TNFα), and interleukin (IL) 6. The reproductive tissues, like all tissues, are negatively 
affected by inflammation. The follicular environment is altered in an obese woman. 
Follicular fluid contains higher levels of insulin, triglycerides, leptin, and markers 
of inflammation such as lactate and CRP [6]. Leptin affects steroidogenic pathways 
in granulosa cells, thus affecting estrogen and progesterone production. This could 
therefore have impact downstream on endometrial receptivity and implantation [6].
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In obese mouse models, the ovaries demonstrate more apoptotic follicles and 
the oocytes themselves are smaller and less likely to be mature. These oocytes 
reveal high rates of meiotic aneuploidy due to fragmented and disorganized meiotic 
spindles and chromosomes that are not properly aligned on the metaphase plate [6].
Independent from this, obesity alters mitochondrial function in the oocyte. 
In an obese mouse model, the mitochondria have a disordered architecture with 
fewer cristae, more vacuoles, and evidence of swelling [19]. These abnormal 
mitochondria show evidence of metabolic stress, which leads to a compensatory 
increase in mitochondrial DNA copy number in obese mice [6, 20]. Obese mice 
also demonstrate evidence of endoplasmic reticulum (ER) stress where their 
cumulous-oocyte complexes have increased ER stress markers and increased 
granulosa cell apoptosis [21].
A possible cause for this cellular and organelle damage in obesity is lipotoxicity. 
Lipotoxicity is a condition where fatty acids from the diet that exceed the storage 
ability of the adipocytes can accumulate in other tissues and cause toxic effects.
Obese women have higher circulating free fatty acids (FFAs), which increase 
reactive oxygen species (ROS) that induce mitochondrial and ER stress and leads to 
apoptosis. Studies have shown that the oocytes of mice have significant increased 
production of ROS along with depleted glutathione levels, which is an important 
intracellular antioxidant defense against ROS [22]. Oocytes exposed to maternal 
obesity or to high levels of FFA in vitro have demonstrated perturbed mitochondria 
with reduced mitochondrial function, which then fail to support normal cleavage 
and embryo development [21].
2.3 Effects of obesity on embryo quality
The preimplantation embryo is also affected by an obese environment. Given 
that the early embryonic development is largely driven by the oocyte, it is not 
unexpected that if the oocyte is negatively affected, then the embryo development 
would be too.
In a mouse model, embryos of obese females have demonstrated slower pre-
implantation development and disordered differentiation to inner cell mass and 
trophectoderm lineage [20].
In an IVF model with autologous oocytes, obese women are more likely to create 
poor quality embryos [23, 24]. One study noted that embryos from women with 
a BMI > 25 kg/m2 were less likely to develop after fertilization and those that did 
reached the morula stage more rapidly. Those that reached the blastocyst stage 
had fewer cells in the trophectoderm and demonstrated poor glucose uptake and 
increased levels of triglycerides along with altered amino acid metabolism com-
pared with embryos from normal weight women (BMI < 25 kg/m2) [25].
Much like oocytes, embryos may also be susceptible to lipotoxicity. Murine 
embryos that are cultured in palmitic acid, the most common FFA present in human 
serum, have fewer nuclei and altered IGF-1 receptor expression [26]. This nega-
tively affects insulin sensitivity and glucose transport at a critical stage in develop-
ment. This study also demonstrated that the trophoblastic cells that are exposed 
to the palmitic acid proliferate less and undergo apoptosis in a dose-dependent 
fashion.
Elevated leptin levels also have a direct negative effect on the developing 
embryo. In vitro studies have demonstrated that leptin has a stimulating effect on 
human trophoblastic cell growth and inhibition of leptin decreases that prolifera-
tion and induces apoptosis [27]. Much like its effect in the brain, tonically elevated 
leptin levels in an obese state may decrease the sensitivity of trophoblastic cells to its 
effect, altering their development.
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However, there are studies in human models that have not demonstrated a nega-
tive effect of obesity on embryo quality, showing no significant difference in the 
quality of transferred embryos between the different BMI groups [28–31]. Although 
it is worth noting that despite the quality of transferred embryos being similar, 
other studies have suggested a reduction in the overall quality of all embryos cre-
ated in an IVF cycle [14, 24], with fewer surplus embryos cryopreserved in an obese 
population compared to women with a normal BMI [14]. A retrospective analysis of 
IVF/ICSI cycles observed that in young women, obesity led to a significant reduc-
tion in average embryo quality, cryopreservation, and also embryo utilization [24]. 
A large retrospective analysis of over 6500 IVF cycles demonstrated no difference 
in embryo quality but did comment that there were poorer outcomes in the obese 
women [31]. Certainly, large prospective trials are required to further elucidate the 
effect of obesity on the embryo.
2.4 Effects of obesity on endometrial receptivity and implantation
There are conflicting data as to whether or not obesity affects endometrial 
receptivity and implantation of embryos, and there are several suggested 
mechanisms.
Leukemia inhibitory factor (LIF) has been implicated in the regulation of 
implantation, and a significant negative correlation between endometrial glan-
dular LIF and BMI has been observed [32]. It has also been suggested that a state 
of relative hyperestrogenemia that is seen in obese women (due to aromatization 
of androgens to estrogen in adipose tissue) may also have a detrimental effect on 
receptivity [32].
Obesity is associated with insulin resistance and hyperinsulinemia. Elevated 
insulin levels have been associated with a reduction on glycodelin and insulin-like 
growth factor binding protein 1 (IGFBP1). Low levels of glycodelin have been 
associated with recurrent pregnancy loss, and IGFBP1 is an integral molecule 
involved in adhesion during implantation [32]. Derangement in these molecules 
may contribute to reduced receptivity in obese women.
As noted previously, obesity is an inflammatory state and obese women have been 
observed to have elevations in proinflammatory cytokines (IL6, TNFα), and these 
inflammatory markers are thought to exert negative effects on implantation [14].
Obese women also have a different pattern of endometrial gene expression dur-
ing implantation than lean women [33], which is more pronounced when examined 
in the context of infertility. It is postulated that this is due to all or some of the 
abovementioned factors and the change in the intrauterine milieu of the obese 
women.
Although there are several plausible mechanisms as to how obesity impacts nega-
tively on endometrial receptivity and implantation, the data for impact on infertility 
are inconsistent and contradictory. The best model for discriminating between the 
obesity effects on oocyte/embryo and endometrium is the oocyte donation model 
[34]. A retrospective review of over 2500 oocyte donation cycles demonstrated a 
negative trend in pregnancy rates with a rising BMI and a statistically significantly 
lower pregnancy rate in overweight and obese women compared to normal weight 
women [35]. However, the implantation rates were considered similar, suggesting 
the difference between groups was due to an increased pregnancy loss rate in the 
obese women. Another study also demonstrated lower live birth rates among obese 
surrogates compared to normal weight women [36]. Other smaller studies have sug-
gested no difference in outcomes in obese oocyte recipients [37].
A case-controlled trial looking at IVF with autologous oocytes observed that 
women with a BMI > 25 kg/m2 had reduced implantation and pregnancy rates along 
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with increased miscarriage rates [38]. Once again, large well-designed prospective 
studies using this model are required to further examine the effect of obesity on 
endometrial receptivity and implantation.
2.5 Effects of obesity on miscarriage
The role of obesity and miscarriage is also debated. Given the recognized impact 
of obesity on both the embryo and the endometrium, it is a reasonable assumption 
that miscarriage rates would be higher in an overweight and obese population.
Several studies have demonstrated ever-increasing odds of miscarriage with 
increasing BMI, in ovulation induction for anovulatory infertility, as well as in IVF 
cycles in both fresh and frozen cycles [28, 17, 39, 40]. A large meta-analysis of over 
47,000 cycles confirmed that overweight or obese women have a higher rate of 
miscarriage compared with normal weight women [41]. This has also been dem-
onstrated in donor oocyte cycles, with higher miscarriage rates in obese recipients 
than in normal weight women [42].
Interestingly, however, a larger follow-up study of over 2600 donor oocyte 
cycles by the same group [43] did not demonstrate a difference in miscarriage rates. 
There was a trend toward a negative impact; however, it was only when a composite 
measure of ongoing pregnancy rate per cycle was calculated that this was shown to 
be significantly lower in the obese population.
A meta-analysis looking at both spontaneous and assisted reproduction pregnan-
cies showed that women with a BMI > 25 kg/m2 had a significantly higher rate of 
miscarriage <20 weeks gestation. Subgroup analysis confirmed this to be in the donor 
oocyte cycles but not across all patients in the studies [44]. Another study demon-
strated that in a group of women with a history of recurrent pregnancy loss (RPL), 
obesity is a well-recognized risk factor for miscarriage in a subsequent pregnancy [45].
A striking study looking at the chromosomal make-up of miscarried specimens from 
patients with RPL demonstrated that obese women had a much higher rate of euploid 
pregnancy loss compared to normal weight women. This supports the theory of the 
impact of obesity on embryo quality and endometrial receptivity.
3. Effects of obesity on male reproduction
Historically, the impact of obesity on reproduction has largely been researched 
in female populations with very little examination of the impact of male obesity. 
There is, however, a growing body of research to indicate that obesity in the male 
is a cause for concern. A systematic review of 30 studies with over 115,000 par-
ticipants found that obese men were more likely to experience infertility and that 
clinical pregnancy and live birth rates per assisted reproduction cycle were reduced.
3.1 Hormonal effects of male obesity
Much like in the female, the hypothalamic-pituitary-gonadal (HPG) axis is dys-
regulated in the setting of male obesity. There is strong evidence of a negative effect 
of obesity on total testosterone, SHBG, and free testosterone [46] as well as reduced 
inhibin B concentrations and diminished luteinizing hormone (LH) pulse ampli-
tude [4]. It is well understood that suppression of SHBG by hyperinsulinemia in 
obese men increases androgen availability for aromatization to estrogen in adipose 
tissue, which may then lead to negative feedback and reduction in gonadotrophin 
secretion [4]. Consequent to this is a decreased Leydig cell testosterone secretion, 
which ultimately affects spermatogenesis.
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The function of the Sertoli cell, which provides both physical and nutritional 
support to the developing germ cell, is also impacted. Adhesion of the Sertoli cell is 
dependent on testosterone, and a reduction in these levels can lead to retention and 
phagocytosis of mature spermatids and ultimately reduced sperm counts. Other 
hormones that influence Sertoli cell function, FSH, LH, inhibin B, and SHBG are all 
lower in obese men [47].
3.2 Effects of obesity on spermatogenesis
The best markers to assess the impact of obesity on spermatogenesis are the 
sperm parameters from the semen analysis (count, motility, and morphology). 
Rodent models clearly demonstrate that diet-induced male obesity leads to reduced 
sperm motility, decreased sperm count, and decreased percentage of sperm with 
normal morphology [47], though some argue that this is indirectly due to altered 
hormonal stimulation.
The impact of male obesity on sperm parameters in humans is more controver-
sial, with many contradicting studies. A review of studies [47] demonstrated vary-
ing results for the impact of male obesity on sperm concentration, morphology, and 
motility. The reviewers commented that there were several significant confounders 
including lifestyle factors such as smoking and alcohol consumption as well as 
cofactors such as the metabolic syndrome, which have all been shown to impact on 
sperm parameters. Most of the cohorts studied come from fertility centers and so 
are biased toward subfertile men, who may differ from the background population. 
Additionally, many studies rely on self-reporting, which can lead to inaccuracies.
A recent systematic review that evaluated 21 studies demonstrated a J-shaped 
correlation between male obesity and sperm count, whereby overweight and 
obesity is associated with higher rates of oligozoospermia and azoospermia [48].
3.3 Effects of obesity on sperm DNA integrity
In addition to sperm parameters, sperm DNA integrity has been found to be 
an important factor for the ability of a sperm to generate a healthy pregnancy 
[49]. Reactive oxygen species (ROS), commonly elevated in subfertile men, 
have been found to impair sperm DNA integrity. This is likely due to the fact 
that sperm are highly susceptible to ROS in the later stages of spermiogenesis as 
they lose the majority of their antioxidant defenses when they shed cytoplasm 
(Figure 1).
Studies have demonstrated that there is a positive correlation between increasing 
adiposity and higher sperm and seminal plasma ROS levels [50–52]. Oxidative stress 
is highly correlated with cumulative damage in the body induced by free radicals 
that are inadequately neutralized by antioxidant mechanisms. Antioxidant enzymes 
include superoxide dismutase (SOD), catalase (CAT), and glutathione S-transferase 
(GST). A recent study in an obese mouse model showed decreased SOD in the 
testicular tissues of obese rats [53].
Studies have also confirmed that male obesity is associated with higher levels of 
sperm DNA damage [47], due to the oxygen-free radical damage, and a direct ther-
mal effect on the testicles due to obesity. It is therefore a reasonable assumption that 
male obesity negatively impacts on sperm DNA integrity via high ROS levels within 
the testis. DNA fragmentation has been proven to reduce male fertility, possibly 
reduce success with assisted reproduction, and increase pregnancy loss.
Although not directly impacting on testicular function, obesity leading to 
reduced testosterone results in a reduction in libido and negatively impacts on 
erectile and ejaculatory function, which all lead to a reduction in fecundity [54].
7Reproductive Consequences of Obesity
DOI: http://dx.doi.org/10.5772/intechopen.80897
4. Transgenerational effects of parental obesity
There is good evidence to show that maternal obesity during pregnancy is a risk 
factor for obesity in the offspring [55]. There is also an increasing body of evidence 
that obesity in males and females periconceptionally can impact on the metabolic 
health and even fertility of future generations. By using animal models, the impact 
of maternal and paternal obesity on offspring and future generations has been 
examined. Studies have demonstrated that obesity and other health conditions can 
be transmitted across multiple generations via epigenetic mechanisms down either 
the maternal or the paternal line.
An elegant murine study by Huypens and others [56] induced obesity in both 
male and female parents for 6 weeks with a high-fat diet (HFD) and then performed 
IVF. Embryos created from all combinations of parents were transferred into a lean 
dam, to negate the impact of obesity during pregnancy (Figure 2).
Female offspring born from both maternal and paternal obese parents gained 
more weight than the male offspring. The risk of female offspring obesity was 
reduced if only the female parent was obese, suggesting an additive effect.
Females from obese parents also had significant metabolic derangements. They 
demonstrated a delay in blood glucose clearance leading to hyperinsulinemia and 
increased fat mass. Male offspring demonstrated severe insulin resistance before 
Figure 1. 
Hypothesis on how epigenetic changes and impact of ROS due to an obese proinflammatory environment can 
occur at multiple different points along the development of the sperm, resulting in altered fertility [47].
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any change in body weight. This insulin resistance was acquired in the offspring via 
the maternal line.
Another study by Fullston and others [57] demonstrated that paternal obesity 
initiated changes to metabolic health and obesity in multiple subsequent genera-
tions. Insulin resistance and obesity were transmitted to both the female and male 
first-generation offspring and then through both parental lineages to the second 
generation with amplified obesity in the female offspring in the first generation and 
in their sons in the second generation.
Epigenetics is the hypothesized mechanism for transgenerational disease 
patterns. It was thought that this was in utero exposure to epigenetic modification 
of offspring DNA or histone modification during developmental stages without 
alteration to the DNA itself. However, this has been broadened to include transgen-
erational (meiotic) alterations and occurs through several possible processes includ-
ing DNA methylation, histone modification, DNA-binding proteins, and noncoding 
RNA [6] (Figure 1).
In the study by Fullston and others [57], they demonstrated that diet-induced 
paternal obesity leads to an alteration in mRNAs and microRNAs within the rodent 
testes, with alteration in the sperm microRNA content as well. They also detected 
Figure 2. 
Embryos created from different combinations of obese and lean parents were transferred into a lean surrogate 
dam, to determine the impact of overweight and obesity in male and female parents on the next generation [55].
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25% reduction in global methylation of germ cell DNA. These modifications are 
potential signals to program obesity and impaired metabolic health in offspring. 
These effects have also been demonstrated in humans with hypomethylation of 
sperm being associated with subfertility [58]. Another study [59] demonstrated, in 
a mouse model of diet-induced obesity, sperm tRNA-derived small RNAs impaired 
offspring glucose tolerance and induced insulin resistance. Other studies have also 
demonstrated that both maternal and paternal obesity can cause epigenetic changes 
that predispose offspring to obesity or metabolic disease later in life [60].
5. Effectiveness of weight loss strategies
There is no doubt that obesity contributes to significant periconceptional and 
perinatal morbidity and has been clearly associated with prolonged time to concep-
tion, increased pregnancy loss, and higher rates of adverse pregnancy outcomes 
such as preeclampsia and gestational diabetes along with preterm birth and in turn 
increased fetal morbidity and mortality. As mentioned previously, there is increas-
ing information that it affects fertility and miscarriage rates so it is not unexpected 
that national and international guidelines focus on weight loss prior to either 
spontaneous conception or assisted reproduction [4, 32, 61] and that first-line 
management is ideally with lifestyle intervention and behavior modification.
5.1 Lifestyle intervention and behavior modification
It is controversial as to whether weight loss through dietary intervention, exer-
cise programs, or behavior modification will impact significantly on spontaneous 
conception rates or success with assisted reproduction. There are a group of studies 
that suggest improved ovulatory frequency, pregnancy rates, and cost per preg-
nancy achieved in assisted reproduction [32, 62]. One randomized controlled trial 
demonstrated that a 12-week diet and exercise program resulted in a mean weight 
loss of 5.4 kg in the intervention group, a trend toward a higher clinical pregnancy 
rate and a significant difference in live birth rates [63]. A secondary analysis of two 
parallel randomized controlled trials in obese PCOS women also demonstrated that 
deferred ovulation induction treatment preceded by lifestyle modification resulted 
in significantly improved ovulation rates and live birth rates when compared with 
immediate treatment [62]. Weight reduction in an obese anovulatory population 
has been shown to improve pregnancy rates. A 6-month lifestyle intervention 
induced an average weight loss of 10 kg, which resulted in return of ovulation in 
90% of participants and 78% conceiving. The miscarriage rate was 18% [64].
However, other studies suggest surprisingly little impact on conception and 
fertility outcomes. One large multicenter randomized controlled trial involving a 
12-week intensive dietary intervention followed by IVF demonstrated a significant 
weight reduction in the intervention group, but this was not reflected in reproduc-
tive outcomes [65]. Live birth rates through IVF and miscarriage rates were not 
significantly different. The authors did note that the spontaneous pregnancy rates 
in the intervention group compared to the immediate treatment group were signifi-
cantly higher. This may, however, have been due to having a longer time to achieve a 
spontaneous pregnancy, albeit they were then older at the time of IVF [65].
Firstly, lifestyle modification often results in only a modest weight loss. In a 
general population large-scale disease prevention programs including intensive 
counseling, support, and changes in diet and exercise, a 4–6 kg weight loss could 
be achieved but was sufficient to reduce the incidence of diabetes and metabolic 
syndrome [66]. Unfortunately, achieved weight loss is often regained relatively 
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quickly [61]. It is reported that weight loss through behavior modification and 
lifestyle change of greater than 10% and sustained for longer than 12 months occurs 
in only 20% of individuals who start a program [67].
Additionally, lifestyle modification has been attributed to positive effects on the 
endocrine and metabolic profile of an individual and that this, and not the weight 
loss, is the cause of the reported improved reproductive outcomes [68]. As such, 
there is a call for caution on delaying fertility treatment to allow lifestyle modifica-
tion and weight loss to occur [69].
5.2 Pharmacological agents
Due to the modest weight loss from lifestyle intervention, pharmacotherapy is 
required as an adjunct to deliver better outcomes. There is good evidence to show that 
it can be used to help manage hypertension, diabetes, and cardiovascular disease in 
the obese population when used in addition to not replacing lifestyle intervention.
National and international bodies concur that these pharmacological agents can 
be used to help with weight loss prior to conceiving in those who are obese or those 
who are overweight with associated weight-related coexisting conditions [4, 32, 61]. 
It is important to note, however, that none of these drugs have been studied in men 
or women before conception and their effects on menstrual cycles, ovulation, or 
even pregnancy rates are unknown.
Phentermine is a sympathomimetic agent that suppresses appetite. Studies 
have indicated significant weight loss at 6 months compared to placebo [70]. There 
are side effects of dry mouth, agitation, insomnia, and tachycardia, and it is not 
recommended in patients with a history of cardiovascular disease. It is the most 
commonly used weight loss drug in Australia and the USA.
Orlistat inhibits pancreatic and gastric lipases and so reduces the absorption of 
dietary fats. It is found to be effective for weight loss [71] but has the side effects of 
fat malabsorption including steatorrhea, fecal incontinence, and fat-soluble vitamin 
deficiency [72].
Liraglutide is a glucagon-like peptide-1 agonist and controls hyperglycemia 
without causing hypoglycemia or weight gain. This drug was initially used to 
treat type 2 diabetes mellitus but its side effect profile of decreased appetite and 
subsequent weight loss led to its use as a weight loss agent. Studies demonstrate 
significant weight loss over placebo and improvement on cardiometabolic param-
eters [73]. Common side effects are nausea, vomiting, and diarrhea, which are dose 
related and diminish over time.
Topiramate, an anticonvulsant, has also been used to treat obesity due to the side 
effect of weight loss and is used as either monotherapy or in combination with phenter-
mine. A naltrexone/bupropion combination has also been demonstrated to provide aver-
age weight loss over 12 months [74], and Lorcaserin, a selective 5-hydroxytryptamine 2c 
receptor agonist, also suppresses appetite with a 3.6% weight loss over a year [75].
All of these agents are contraindicated in pregnancy.
One agent not contraindicated in pregnancy is metformin. Metformin is a bigua-
nide that inhibits hepatic glucose production and increases peripheral tissue sensitivity 
to insulin, resulting in a reduced circulating insulin and accompanying decreased body 
weight. Although not intended as a weight loss agent, it is known to reduce weight by 
1–2 kg alongside a low-calorie diet and its safety in pregnancy is well studied [61].
Many obese men and women also self-medicate with herbal supplements 
although their safety and effectiveness have not been demonstrated.
Unfortunately, much like with lifestyle intervention and behavior modification 
strategies, weight loss is modest at best, and dropout rates with these medications 
due to time and also side effects typically exceed 30% [76].
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5.3 Bariatric surgery
There is an increasing number of bariatric surgical procedures being performed 
worldwide with nearly 200,000 cases being reported recently [77]. The surgeries 
vary between restrictive, such as the sleeve gastrectomy or the laparoscopic adjustable 
gastric banding and the malabsorptive procedures such as biliopancreatic diversion 
or a mixed restrictive/malabsorptive procedure such as the Roux en Y gastric bypass. 
Bariatric surgery is considered with morbid obesity (BMI > 40 kg/m2) or with 
BMI > 35 kg/m2 with concomitant medical conditions exacerbated by obesity [61].
The benefits of bariatric surgery include significant and long-term weight loss. 
The latest IFSO report demonstrated mean weight loss of 30% at 1 year postsurgery 
[77], and the Swedish Obese Study [61] showed significant weight reduction was 
maintained even after 10 years of follow-up [78]. Additionally, bariatric surgery has 
been shown to improve endocrine and metabolic profiles [61].
In women, bariatric surgery has been shown to improve menstrual regularity 
[79], correct ovulation [80], improve clinical and biochemical hyperandrogenism 
along with hyperinsulinemia and glycemic control, and improve both sexual func-
tion along with pregnancy rates [81–83].
In men, bariatric surgery improves hormone profiles by increasing testoster-
one and decreasing SHBG and estradiol [84]. Studies have not demonstrated an 
improvement in sperm quality, and in fact there have been case reports that have 
shown a deterioration on sperm parameters following surgery, likely due to nutri-
tional deficiencies [48, 85]. This is in opposition to findings of longer-term stable 
sperm parameters following significant weight loss postbariatric surgery [86]. 
There is no doubt that more research needs to be done in this area to clarify this 
impact on male fertility.
The obstetric impact of bariatric surgery is profound with the risks of complica-
tions such as gestational diabetes, preeclampsia, and fetal macrosomia significantly 
reduced following surgery when compared to morbidly obese women [61]. Rare 
surgical complications (bowel obstruction, herniation, band events, and surgical 
line strictures) have been reported in pregnancy due to intra-abdominal pressure, 
displacement from the gravid uterus, and even hyperemesis [87, 88]. However, 
nutritional deficiencies due to malabsorptive-type surgery or noncompliance with 
long-term supplementation can have a significant effect on fertility and pregnancy 
outcomes. Deficiencies in iron, vitamin A, vitamin D, vitamin B12, vitamin K, 
and calcium can lead to maternal complications (e.g., anemia, osteopenia) and 
fetal complications (e.g., congenital abnormalities) [87]. Although there are no 
randomized prospective trials addressing time to conception after bariatric surgery, 
it is suggested to delay pregnancy 1–2 years postsurgery to avoid fetal exposure to 
nutritional deficiencies from rapid maternal weight loss [87, 89–91]. A large age and 
BMI-matched cohort study has demonstrated that the chance of preterm birth and 
small-for-gestational age (SGA) singletons were greater in women with a history of 
bariatric surgery than in women without such surgery and that the risk of still birth 
or neonatal death was slightly higher in the bariatric surgery group as well [92]. The 
median time from surgery to conception was 1.1 years. There does not appear to be 
any significant differences in obstetric or perinatal outcomes when comparing the 
different bariatric surgery procedures [93].
There are, however, studies comparing pregnancies conceived less than 1 year 
after bariatric surgery to those conceived greater than 1 year after surgery and 
found no difference in bariatric complications, pregnancy related, or perinatal 
outcomes [93, 94]. Therefore, when considering advanced age of the woman, the 
benefits of postponing pregnancy must be balanced against the risk of declining 
fertility due to age [4, 61].
Obesity
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6. Conclusion
Obesity is increasing globally in men and women, and the negative impact of 
overweight and obesity on reproductive health, fertility, pregnancy outcomes, 
and also transgenerational health is significant. Obesity impairs both natural and 
assisted conception and has been found to affect endocrine function, oocyte and 
sperm quality, embryo quality, and also endometrial receptivity and implantation. 
Pregnancy and live birth rates are lower, and miscarriage rates are higher in the 
setting of obesity. The metabolic and reproductive health of the offspring is also 
negatively affected by both maternal and paternal obesity.
Preconceptional weight loss is recommended for all women seeking fertility 
treatment, firstly through counseling, lifestyle intervention, and behavior modifi-
cation and then with adjunctive pharmacological agents or bariatric surgery, with 
a delay to conception of at least 1 year following this. Careful consideration of the 
benefits of delaying conception for weight loss must be balanced against the pos-
sibility of declining fertility due to advancing age of the couple.
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